Staidson (Beijing) Biopharmaceuticals Co., Ltd. (300204)
XSHE XSHE Primary Summary
300204 Chart
People also search for
Staidson (Beijing) Biopharmaceuticals Co., Ltd. (300204) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Staidson (Beijing) Biopharmaceuticals Co., Ltd. ever had a stock split?
Staidson (Beijing) Biopharmaceuticals Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Wang Chao CEO | XSHE Exchange | CNE100001237 ISIN |
| CN Country | 492 Employees | 17 May 2019 Last Dividend | 5 May 2016 Last Split | 15 Apr 2011 IPO Date |
Overview
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is a prominent player in China's pharmaceutical industry, specializing in the creation, manufacturing, and distribution of innovative therapeutic drugs. Since its inception in 2002, the company has carved out a niche in the competitive biopharmaceutical landscape by focusing on a range of diseases. Operating from its headquarters in Beijing, China, Staidson BioPharmaceuticals has dedicated itself to advancing pharmaceutical science and improving patient care through its robust R&D capabilities and extensive portfolio of drug products.
Products and Services
Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s product portfolio encompasses a diverse range of therapeutic solutions aimed at addressing complex health challenges:
- Protein Drugs: The company specializes in the research and development of protein-based medicines, with a significant emphasis on therapeutic monoclonal antibody drugs. These advanced biological drugs offer targeted treatment options for various diseases, utilizing antibodies engineered to attack specific pathogens or diseased cells without harming healthy tissues.
- Gene Therapy/Cell Therapy Drugs: Staidson BioPharmaceuticals is at the forefront of gene and cell therapy research, pioneering treatments that modify or replace defective genes or utilize beneficial cells to treat disease. This innovative approach holds promise for addressing genetic disorders, certain cancers, and other conditions that have been challenging to treat with traditional therapies.
- Chemical Drugs: In addition to its focus on biologics, the company also develops and markets chemical drugs, which are synthesized from chemical substances and have a long history of use in treating a wide range of conditions. Staidson BioPharmaceuticals applies modern pharmaceutical science to improve the efficacy and safety of these drugs.
Staidson (Beijing) BioPharmaceuticals Co., Ltd. takes pride in offering its pharmaceutical products across various therapeutic areas, including but not limited to, nervous system disorders, infectious diseases, gastrointestinal issues, urinary system conditions, and autoimmune diseases. This broad spectrum of focus reflects the company's commitment to addressing unmet medical needs and enhancing health outcomes for patients worldwide.
